Stay updated with breaking news from Junshi Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting
-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in...
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency
-- 2nd MAA submission in Europe reflects toripalimab's steady yet speedy progress towards global commercializationSHANGHAI, China, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd